Home  |  Search:
Home > Immediate Funding Opportunities

BARDA - Chemical Biological Radiological Nuclear BAA

Upcoming deadline: This BAA is a continuously open announcement valid throughout the period from the date of issuance through 3 March 2012.


Scope: To support the advanced research and development of medical countermeasures for chemical, biological, radiological, and nuclear agents that threaten the U.S. civilian population.


Funding: Anticipated funding for the program (not per contract or award) may range from $5M to $750M dollars subject to congressional appropriations.

Michael J. Fox Foundation

Target Validation
Pre-Proposal Receipt Date: November 29, 2011
Full Application Invitation: January 11, 2012
Application Receipt Date: March 1, 2012
Anticipated Award Announcement: May 2012
Anticipated Funding: June 2012
http://www.michaeljfox.org/research_openFundingPrograms_program.cfm?ID=45
 
Therapeutics Development Initiative
Pre-Proposal Receipt Date: November 29, 2011
Full Application Invitation: January 11, 2012
Application Receipt Date: March 1, 2012
Anticipated Award Announcement: May 2012
Anticipated Funding: June 2012
http://www.michaeljfox.org/research_openFundingPrograms_program.cfm?ID=46
 
Clinical Intervention Awards
Pre-Proposal Receipt Date: October 11, 2011
Full Application Invitation: January 11, 2012
Application Receipt Date: March 15, 2012
Anticipated Award Announcement: June 2012
Anticipated Funding: July 2012
http://www.michaeljfox.org/research_openFundingPrograms_program.cfm?ID=43
 
 

Repositioning Drugs for PD 2011

Upcoming deadline: A conference call to find out more about the program will take place on October 18, 2011 - 12:00pm US EDT or at 7:00pm EDT on the 18th.
To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details. Pre-proposals will be due on December 15, 2011 at 6:00pm US ET.

Scope: To seek projects that will test drugs that are either already FDA-approved or that have been proven safe in a clinical trial for a certain indication, to determine whether the drug might be efficacious in the treatment of PD.

Funding: MJFF will commit up to $3 million to fund applications submitted in response to this RFA. However, awards pursuant to the RFA are contingent upon the availability of funds and the receipt of a sufficient number of applications of high scientific merit that meet the requirements of the RFA. MJFF intends to fund multiple proposals as part of this initiative although it would consider funding a single high-impact proposal if appropriate.
 
 
 **To see all this info in one spot, please see the Funding Opportunities Section of our website:

Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)

Upcoming deadline: September 14, 2011; September 14, 2012

Scope: To develop new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare nerve agents such as sarin and VX, and toxic industrial chemicals and pesticides such as cyanide, chlorine, parathion, and sodium fluoroacetate.

Funding: The expected direct cost for individual awards is $300,000-$500,000 per year for up to five years.

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54)

Upcoming deadline: September 14, 2011; September 14, 2012

Scope: To develop new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare nerve agents such as sarin and VX, and toxic industrial chemicals and pesticides such as cyanide, chlorine, parathion, and sodium fluoroacetate.

Funding: The expected direct cost for individual awards is $1.5-2.5 million per year for a total of $7.5-12.5 million over a five-year project period.
 

Improved Diagnostic Capabilities for Select Biodefense and Emerging Pathogens (R21/R33)

Upcoming deadline: July 14, 2011

Scope: To support basic to translational research focused on development of improved and/or field-appropriate diagnostic capabilities for select biodefense and emerging pathogens.
Responsive applications will define and address a diagnostic insufficiency; applications that address a field-specific deficiency are of particular interest.

Funding: $275,000 over the R21 two-year period. $300,000 in direct costs per year and cannot exceed three years.
                The NIAID anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.

Development of Technologies that Accelerate the Immune Response to Biodefense Vaccines

Upcoming deadline: June 23, 2011

Scope: To support the advanced development of candidate products, consisting of a vaccine component and a technology that accelerates the immune response, for diseases caused by NIAID Category A and B Priority Pathogens excluding B. anthracis.

Funding: The NIAID estimates that multiple cost reimbursement, completion type contracts may be issued for a total cost of up to $44.5 million for a five-year period of performance beginning on or about April 1, 2012.

Chemical Approaches to Target Validation for Drug Resistant Pathogens (R01)

Upcoming deadline: June 15, 2011


Scope: To support research focused on using chemical tools to either address scientific questions about microbial biological processes and host-pathogen interactions and/or determine the biological activity of host or pathogen proteins.


Funding: Budgets may be requested for up to $750,000 direct costs per year for up to 5-years.

An Integrated Approach to Understanding Host-Pathogen Interactions

Upcoming deadline: June 6, 2011


Scope: To establish multi-disciplinary centers that focus on understanding at a molecular level the host-pathogen interaction using a systems biology approach.
The primary goal of the activities carried out under this contract will be to investigate and identify the metabolic, regulatory, signaling, and other biological pathways generated by host-pathogen molecular interactions to help explain and predict clinical manifestations of infectious diseases, host responses, disease progression, and outcomes


Funding: Multiple-year Cost-Reimbursement type Level of Effort contract with a term of 5 years.

Targeting Resistance in Select Gram-Negative Pathogens (R21/R33)

Upcoming deadline: May 26, 2011

Scope: To support basic-translational research focused on development of antibacterial technologies designed to circumvent resistance in select gram-negative pathogens. One example of such a therapy already in widespread clinical use is ß-lactamase inhibitors.

Funding: Direct costs are limited to $275,000 over an R21 two-year period
The R33 award phase is limited to $300,000 in direct costs per year and cannot exceed three years.

Autonomous Diagnostics to Enable Prevention and Therapeutics: Diagnostics on Demand – Limited Resource Settings (ADEPT: DxOD - LRS)

Upcoming deadline: May 19, 2011
Scope: DARPA is soliciting proposals to develop new diagnostic capabilities as components of the ADEPT program. In these solicitations, DARPA is seeking proposals for new methods to enable devices that can address present unmet clinical needs as well as decrease the time to design, manufacture, and distribute valid new assays when future needs for individual assessment for health or performance arise.

Funding: Multiple awards are anticipated. The amount of resources made available under this BAA will depend on the quality of the proposals received and the availability of funds.

Autonomous Diagnostics to Enable Prevention and Therapeutics: Diagnostics on Demand – Point of Care (BAA)

Upcoming deadline: May 17, 2011

Scope: This announcement, “Autonomous Diagnostics to Enable Prevention and Therapeutics: Diagnostics on Demand – Point of Care”, focuses specifically on the second objective: Development of highly multiplexed devices appropriate for medical facilities.

Funding: Multiple awards are anticipated. The amount of resources made available under this BAA will depend on the quality of the proposals received and the availability of funds.



Advanced Research and Development of Medical Countermeasures for Pandemic Influenza (BAA)

Solicitation release date: March 28, 2011

Award Date: September 2011

Scope: To support advanced development activities to improve candidate products and diagnostic tools and incorporate considerations of the challenging lifecycle requirements of these products before and during a pandemic (e.g. shelf life, storage, distribution, and dispensing).

Funding: Budget requests should reflect the nature and complexity of the proposed research


Partnerships for Biodefense (R01) RFA-AI-11-014

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-014.html

 Upcoming deadline:  May 27, 2011 

Funding: $750,000 per year may be requested for a maximum period of 5 years.
In addition, applicants may request up to a total of $300,000 for major equipment in the first year of the award.

Scope: The Purpose is to support preclinical development of lead candidate vaccines, therapeutics, adjuvants or diagnostics against NIAID Category A, B, or C priority agents. 

 Applications must:
1) Demonstrate substantive investment by at least one industrial participant.
2) Include a Product Development Strategy attachment.

Clinical Sequencing Exploratory Research (U01)

Upcoming deadline:  March 3, 2011 
Funding: $1.5M direct costs per year for up to 4 years
Scope: Application of genomic sequence data to the care of patients. Applications are expected to address critical questions about the application of genomic sequencing to clinical care of individual patients, from generation of genomic sequence data, to interpretation and translation of the data for the physician, to communication to the patient, including an examination of the ethical and psychosocial implications of bringing broad genomic data into the clinic.

NIAID Clinical Trial Implementation Cooperative Agreement (U01)

http://grants1.nih.gov/grants/guide/pa-files/PAR-10-186.html

 

Upcoming deadlines:  May 13, 2011; September 13, 2011

 

Funding: preapproval is required for direct costs over $500,000 per year. Up to 5 years.

 

Scope: To support implementation of trials that address high priority research related to the mission and goals of NIAID and that are considered high-risk by the NIAID. 

 

A high-risk clinical trial is defined by the NIAID as having one or more of the following attributes:   

·         provision of a non-routine intervention, that is, an intervention or non-routine use of an intervention that would not otherwise be provided for the condition under study in the local facility where the study is being conducted;

·         administration of an unlicensed product; or

·         administration of a licensed product for an unapproved indication.

 

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-096.html

 

Upcoming deadlines:  February 5;  June 5;  October 5 

 

Funding: preapproval is required for direct costs over $500,000 per year. for up to 5 years.

 

Scope: To support investigator-initiated multi-site Phase II or Phase III randomized, controlled clinical trials. The trials may address any research question related to the mission and goals of NHLBI and may test clinical or behavioral interventions.

 

All multi-site randomized controlled trials with direct costs of $500,000 or more (excluding consortium F&A costs) in any year must include plans to submit at least two applications, one of which is for the support of a Clinical Coordinating Center (CCC) and the other which is for support of a Data Coordinating Center (DCC).

 

NHLBI Clinical Trial Pilot Studies (R34)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-005.html

 

 

Upcoming deadlines: February 16 ; June 16; October 16

 

Funding: Direct costs are limited to $450,000 over up to three-years, with no more than $225,000 in direct costs allowed in any single year.   

 

Scope: to conduct pilot studies to obtain data that is critical for the design of robust clinical trials.  Applications must demonstrate that the proposed pilot studies are both necessary and sufficient to permit the design of the clinical trial.

 

NIAID Clinical Trial Implementation Grant (R01)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-184.html

 

Upcoming deadlines: February 5; June 5  ; October 5

 

Funding: preapproval is required for direct costs over $500,000 per year. Up to 5 years.

 

Scope:  To support implementation of trials that address high priority research related to the mission and goals of NIAID and that are considered non-high-risk by the NIAID.

 

A non-high-risk trial would not have any of the attributes listed above; for example, it would involve provision of a routine intervention and administration of a licensed product for an approved indication

 

NIAID Clinical Trial Planning Grant (R34)

http://grants1.nih.gov/grants/guide/pa-files/PAR-10-185.html

 

Upcoming deadlines:  May 13, 2011; September 13, 2011

 

Funding: Direct costs can be requested up to $150,000 for a period of one year.

 

Scope: To propose planning, design, and preparation of documentation necessary for implementation of investigator-initiated clinical trials.

 

 

Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-161.html

 

Upcoming deadlines: November 8, 2011; November 8, 2012

 

Funding: the approximate range of funding in direct cost is estimated to be $1.5 to $2.5million per year.
Up to 5 years.

 

Scope: to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV

 

Vaccines: to initial clinical trials by providing the critical resources necessary for achieving this goal. 

 

NIDDK Multi-Center Clinical Study Implementation Planning Grants (U34)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-197.html

 

Upcoming deadlines: June 28, 2011; March 15, 2012

 

Funding: direct costs are limited to $250,000 per year for up to two years.

 

Scope:  The U34 planning grant is designed to:

·          permit early peer review of the rationale for the proposed clinical study

·          permit assessment of the design and protocol of the proposed study

·          provide support for the development of documents needed for the conduct of the study, including a manual of operations

·          support the development of other essential elements required for the conduct of a clinical study.


Completion of the required products of a U34 grant is a prerequisite for submission of a multi-center clinical study cooperative agreement (U01) application.

 

NINDS Exploratory Clinical Trials (R01)

 http://grants.nih.gov/grants/guide/pa-files/PAR-10-199.html

 

Upcoming deadlines: February 5th;  June 5th; October 5th

 

Funding: Direct costs can be requested up to $500,000 per year for up to 5 years. Annual direct costs over $500,000 require preapproval from the institute.

 

Scope:  investigator-initiated exploratory clinical trials, Phase I and II, to address research questions related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or surgical, behavioral or rehabilitation therapies.

 

NINDS PHASE III Investigator-Initiated Multi-Site Clinical Trials (U01)

http://grants.nih.gov/grants/guide/pa-files/PAR-10-198.html

 

Upcoming deadlines:  February 5th;  June 5th; October 5th

 

Funding: Direct costs can be requested up to $500,000 per year for up to 5 years. Annual direct costs over $500,000 require preapproval from the institute.

 

Scope:  investigator-initiated, multi-site, randomized, controlled Phase III clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS).  The trials may address any research question related to the mission and goals of the NINDS.

NINDS requires the submission of separate applications for the Clinical Coordinating Center (CCC) and the Data Coordinating Center (DCC).  Separate applications for core functions (e.g., imaging centers, quality of life/economic analyses) may be submitted, but are not required.